338 related articles for article (PubMed ID: 1719330)
21. Immunologic markers and the diagnosis of prostatic cancer.
Ban Y; Wang MC; Chu TM
Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer].
Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T
Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188
[TBL] [Abstract][Full Text] [Related]
23. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy?
Kiran PR
Aust Fam Physician; 2001 May; 30(5):458-60. PubMed ID: 11432019
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
25. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
Barak M; Mecz Y; Lurie A; Gruener N
J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
[TBL] [Abstract][Full Text] [Related]
27. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
[TBL] [Abstract][Full Text] [Related]
28. Screening for adenocarcinoma of the prostate.
Miles BJ
Henry Ford Hosp Med J; 1989; 37(1):5-7. PubMed ID: 2475458
[No Abstract] [Full Text] [Related]
29. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
[TBL] [Abstract][Full Text] [Related]
30. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
Miki M
Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
[TBL] [Abstract][Full Text] [Related]
31. Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers.
Rubenstein M; Guinan PD; McKiel CF; Dubin A
Clin Physiol Biochem; 1988; 6(5):241-52. PubMed ID: 2465864
[TBL] [Abstract][Full Text] [Related]
32. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
Yoshiki T; Okada K; Oishi K; Yoshida O
Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
[TBL] [Abstract][Full Text] [Related]
34. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma.
Larson A; Fritjofsson A; Norlén BJ; Gronowitz JS; Ronquist G
Scand J Clin Lab Invest Suppl; 1985; 179():81-8. PubMed ID: 2417306
[No Abstract] [Full Text] [Related]
35. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Svanholm H; Hørder M
Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
[TBL] [Abstract][Full Text] [Related]
37. [Prostate-specific antigen (PSA) is a valuable marker--if correctly used].
Ekman P
Lakartidningen; 1991 Jun; 88(24):2207-8. PubMed ID: 1711643
[No Abstract] [Full Text] [Related]
38. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].
Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D
Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127
[TBL] [Abstract][Full Text] [Related]
39. Laboratory assessment of prostate status.
Saito Y
Clin Lab Med; 1993 Mar; 13(1):279-86. PubMed ID: 7681740
[TBL] [Abstract][Full Text] [Related]
40. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
